drug · antibody
petosemtamab
Phase 3updated 6mo agoby Merus NV🔗 ChEMBL
Phase 3community read0 votes
Antibody drug with a maximum clinical stage of Phase 1, with 1 investigational indication.
all catalysts(0)
nothing on the calendar yet
Trials studying petosemtamab
- phase3A Phase 3 Study to Evaluate Petosemtamab Plus Pembrolizumab vs Pembrolizumab in First-line Treatment of Head and Neck Cancer (LiGeR - HN1)
- phase3Study of Petosemtamab Plus Chemotherapy Versus Cetuximab or Bevacizumab Plus Chemotherapy in RAS and BRAF Wild Type, Recurrent, Unresectable or Metastatic Colorectal Cancer (LiGeR-CRC2)
- phase3A Phase 3 Study to Evaluate Petosemtamab Compared With Investigator's Choice Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma Patients (LiGeR-HN2)
- phase3Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer
- phase2Study to Investigate Petosemtamab in Adults With Metastatic Non-Small Cell Lung Cancer
News(7)
- Genmab soars to record highs after cancer drug succeeds in key trialThe drugmaker’s market value swelled by more than $7 billion on findings suggesting a recently-acquired medicine could become a new treatment standard for a form of head and neck cancer.biopharma_dive · 18d ago
- Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 19d ago
- Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readoutAnalysts hailed the Phase 3 head and neck cancer results as a big victory for an asset central to Genmab’s growth plans.biospace · 19d ago
- Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3Capping off a busy few days in Spain, Genmab reported results from the first interim analysis of a phase 3 trial showing that adding its bispecific antibody petosemtamab to Merck & Co.'s Keytruda c…fiercebiotech · 19d ago
- Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trialExtending both progression-free and overall survival, Genmab’s Rina-S “sets a high bar for future competition” in a market served by AbbVie, analysts said.biospace · 21d ago
- ESMO: Why Incyte sees itself ‘neck and neck’ with RevMed in KRAS G12D pancreatic cancer raceIncyte has pointed to a spread of phase 1 data for its KRAS G12D inhibitor as evidence that the company has a worthy rival to Revolution Medicines in this increasingly competitive cancer space.fiercebiotech · 23d ago
- Epkinly data only one of Genmab's make-or-break readouts ahead of steep sales erosionBracing for patent losses on its cornerstone product Darzalex, Genmab has bet its future on three cancer programs that will deliver pivotal readouts in quick succession.biospace · 28d ago
Data sources
last refreshed 4h ago
Found something off?
comments(0)
5-min edit window · permanent after that